Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy
2005; Lippincott Williams & Wilkins; Volume: 112; Issue: 2 Linguagem: Inglês
10.1161/01.cir.0000146788.30724.0a
ISSN1524-4539
AutoresRobert Roberts, Ulrich Sigwart,
Tópico(s)Cardiovascular Effects of Exercise
ResumoHomeCirculationVol. 112, No. 2Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBCurrent Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy Robert Roberts, MD and Ulrich Sigwart, MD Robert RobertsRobert Roberts From the Baylor College of Medicine, Houston, Tex (R.R.), and the Centre and Division of Cardiology, University Hospital, Geneva, Switzerland (U.S.). and Ulrich SigwartUlrich Sigwart From the Baylor College of Medicine, Houston, Tex (R.R.), and the Centre and Division of Cardiology, University Hospital, Geneva, Switzerland (U.S.). Originally published12 Jul 2005https://doi.org/10.1161/01.CIR.0000146788.30724.0ACirculation. 2005;112:293–296Hypertrophic cardiomyopathy (HCM), a relatively common genetic disease, is the most common cause of sudden cardiac death (SCD) in young people. The estimated prevalence is 1 in 500. The proportion of individuals inheriting the disease (familial) as opposed to developing a de novo mutation (sporadic) remains to be determined. Nevertheless, because all HCM is genetic in origin, even individuals with the sporadic form will transmit the gene to their offspring and become part of the familial pool. Cases with outflow tract obstruction are referred to as hypertrophic obstructive cardiomyopathy (HOCM) and those without obstruction as HCM. Symptoms occur earlier and are more severe in patients with obstruction.1 The overall annual death rate in patients with HCM is estimated at ≈1%/year, whereas that in patients with HOCM is ≈2%/year, with the risk of stroke being 4-fold greater than it is in patients with HCM.1PathogenesisHCM is characterized by hypertrophy and fibrosis occurring without known cause. The primary abnormality responsible for HCM is a genetic defect. The pattern of inheritance is autosomal dominant, which means that only one of the alleles is defective. The mechanism remains somewhat controversial. The proposed predominant mechanism is that the defective allele acts as a poisonous peptide, which interferes with the normal allele, referred to as a dominant negative. Another mechanism is a gain of function that dominates the normal function. A final mechanism is haploinsufficiency, in which the remaining normal allele provides insufficient protein to perform the function required. The genes responsible for HCM are listed in Table 1. TABLE 1. Genes Responsible for HCMβ-MYCCardiac troponin TMyosin-binding protein Cα-tropomyosinCardiac troponin IMyosin light chains 1–2α-Cardiac actinTitinα-MYCLIMExcessive cardiac growth, reflected by increased myocyte size (hypertrophy), increased the number of fibroblasts with secretion of collagen (fibrosis) and malalignment of myocytes and sarcomeres in the pathology of HCM. The molecular events triggered by the genotype that induce this phenotype remain to be determined. Recently, Gollub's investigative group identified several families with a phenotype of Wolff-Parkinson-White syndrome, conduction abnormalities, and hypertrophy.2 The responsible gene encodes for the α2 subunit of AMP kinase, and this has since been confirmed by others in several families with the same phenotype.3 AMP kinase does not encode for a sarcomere protein, and the associated hypertrophy (presumably because of a metabolic defect) does not show myocyte or sarcomere disarray. Thus, disarray may well be a hallmark of HCM because of defects in sarcomere proteins. This may in fact be an important distinction.The mutant protein from several mutations that are known to cause human HCM has been shown to be incorporated into the cardiac myofibril of feline cardiomyocytes,4 hearts of transgenic mice, and transgenic rabbits.5 Mutations in β-myosin heavy chain (βMYC) have been shown to involve several domains that are critical to the contractility of the sarcomere, such as the actin-binding site, ATP generation, and calcium sensitivity,5 which could predispose to an alteration in cardiac contractility. All of the models expressing a human mutation consistently exhibit disarray, increased fibrosis, and hypertrophy, whereas hypertrophy, which is minimal in the mouse model, is abundant in the transgenic rabbit.5 That the mouse heart has α-myosin heavy chain and the human heart expresses βMYC may explain why the hypertrophy is minimal. In contrast, in the transgenic rabbit, which normally expresses βMYC, expression of the human βMYC mutation is associated with a phenotype that is identical to that of the human, namely hypertrophy, fibrosis, disarray, increased incidence of SCD, and altered ventricular function. Growth factors are consistently upregulated in the human phenotype with HCM and in the genetic animal models.5 The well-recognized fetal isoforms of proteins expressed in pressure overload hypertrophy also are expressed in human HCM, including C-fos, C-jun, and C-myc,6 atrial and brain naturidic peptides,7 and endothelin I.5 The local ventricular pressure plays a significant role in inducing the phenotype of HCM. Despite the mutant protein being present in the same abundance in the right and left ventricles, hypertrophy in 80% to 90% of the cases is confined to the higher-pressure chamber of the left ventricle. Ventricular pressure as a stimulus for hypertrophy has been documented in a variety of clinical situations. Follow-up of HCM patients after the elimination of the outflow tract gradient by septal alcohol ablation exhibited significant reduction in wall thickness, cardiac mass, and myocardial collagen.8 These studies indicate that the phenotype is the result of a defect in the sarcomere protein. The defective protein is incorporated into the intact filaments of the sarcomere and could potentially act as a poisonous peptide. An interaction takes place between local environmental factors such as pressure and the defect to induce the resulting phenotype. Other genes referred to as modifier genes also interact to induce the phenotype.9The effect of these mutations on cardiac function varies from impaired to enhanced contractility. Expression of a βMYC mutant gene in intact feline cardiac myocytes showed sarcomeric disarray after 72 hours.4 Expression of a troponin T mutation in feline myocytes exhibited impaired contractility after 24 to 48 hours, followed by sarcomere disarray.10 Mutant troponin T expressed in adult cardiac rat myocytes11 exhibited decreased cell shortening and impaired contractility. A genetic animal model of HCM induced by expression of a troponin T mutation showed that cardiac contractility was impaired before the development of sarcomere disarray.5 In addition, several studies have shown enhanced contractility because of the expression of mutant βMYC both in vitro and in vivo.5 The molecular abnormality has varied from increased to decreased calcium sensitivity, altered ATP binding, or altered filament binding. The primary genetic defect encoded into the sarcomere protein alters the function of the sarcomere through mechanisms such as calcium binding, which makes the heart susceptible to environmental (eg, pressure) and other genetic effects that lead to the growth response. In response to growth factors, increased fibril blast and secretion of matrix proteins such as collagen, myocyte hypertrophy, and further alteration in cardiac function occur. Disarray may or may not precede the growth response, although evidence suggests that it usually does. The Figure provides a postulated framework for incorporating present observations and stimulating further research. The outstanding questions to be answered are what is the initial stimulus that gives rise to cardiac growth and is the stimulus preceded by altered contractility? Download figureDownload PowerPointGenetic defect (primary abnormality) initiates alteration in myocardial function. This triggers variety of growth responses that lead to myocyte hypertrophy and fibrocyte proliferation, which is further enhanced by interaction with environmental and other genetic factors. AT indicates angiotensin II; IGF, insulin-like growth factor.Medical TherapyNo proven therapy exists for HCM because no appropriate clinical trials have been performed. Treatment for HCM is directed toward the relief of symptoms.12 The first line of treatment is β-blockers (eg, propanolol at 200 to 400 mg/d). The other form of therapy is calcium channel blockers, with verapamil (200 to 400 mg/d) preferred, although diltiazem also is used often. Clinicians have expressed concern, however, about administering verapamil in patients with HOCM because of its dilation. Nifedipine is generally contraindicated because of its vasodilatation. Nitroglycerin and other vasodilating agents are contraindicated in HCM, particularly HOCM. Disopyramide (300 to 600 mg/d) has been used successfully in the treatment of HOCM. Angiotensin-converting enzyme inhibitors and angiotensin II blockers, because of their vasodilating properties, have been discouraged. Unfortunately, most therapies were developed to target HOCM, in which vasodilators may be deleterious. SCD is all the more tragic because it is often the first evidence of the disease and occurs in young individuals who are otherwise in good health. The preferred treatment is an implantable cardioverter-defibrillator. The guidelines for the indication of a defibrillator are cardiac arrest, spontaneous sustained or nonsustained ventricular tachycardia, family history of premature sudden death, unexplained syncope, left ventricular thickness ≥30 mm, and abnormal blood pressure during exercise. If a defibrillator is not available, then sotalol and amiodarone can be considered.Surgical Treatment of HOCMThe treatment for HOCM is myectomy, which relieves symptoms and improves exercise tolerance, and the benefit is usually sustained. The complications are few and the postoperative mortality is 1% to 3% when myectomy is performed by an experienced surgeon in a comprehensive care setting. The procedure has been performed in >2000 patients and has been consistently effective. By convention, surgery is recommended for patients who are symptomatic with a documented at-rest outflow tract gradient of ≥30 mL/mm Hg.Dual Chamber PacingDual chamber pacing in HCM was assessed in 3 randomized crossover studies by activating and deactivating pacemakers accordingly.12 These studies showed that pacing significantly reduced the outflow gradient by 25% to 40%, but the variation among individual patients was substantial. Overall, the data did not support dual chamber pacing as a primary treatment for severely symptomatic patients with HOCM. In patients in whom medical therapy is not effective and surgery or septal ablation for whatever reason is not appropriate, however, it should be considered.Septal Alcohol AblationSeptal alcohol ablation, first reported in 1995, has evolved to become common, with >4000 patients having undergone the procedure.13 The procedure consists of coronary arteriography followed by the placement of a balloon catheter into the first major septal perforator via a 0.014-in flexible guide wire.14 A temporary pacing catheter is positioned in the right ventricle. After the balloon is inflated, an arteriogram is performed through the lumen to verify that the balloon is in the desired anatomical position and to ensure that no alcohol leaked to the left anterior descending coronary artery or the coronary venous system. Contrast echocardiography is used to assess the extent of tissue supplied by the septal artery. The amount of ethanol injected usually is in the range of 1 to 3 cm3. The amount of damage induced is usually such that peak plasma creatine kinase does not exceed 1200 U/L. The success rate for this procedure is >90%, and the incidence of complications is minimal. Patients should be observed in the coronary care unit for 24 hours, and the temporary pacing wire should be removed at the end of this period in the absence of atrioventricular block. The patient may then be transferred to a telemetry unit for the remainder of the hospital stay or discharged. The criteria for patient selection are detailed in Table 2. Some positive experience with septal alcohol ablation has been reported in patients with midventricular obstruction, although this occurrence is rare and requires further study. TABLE 2. Patient Selection Criteria for Septal Alcohol AblationNYHA indicates New York Heart Association; CCS, Canadian Cardiovascular Score.NYHA or CCS class III or IV, despite adequate drug therapy with resting gradient of >30 mm Hg or ≥60 mm Hg under stressNYHA or CCS class II with a resting gradient of >50 or >30 mm Hg and ≥100 mm Hg under stressSymptoms resulting from left ventricular obstruction after discontinuing medication because of side effectsPrevious unsatisfactory surgical myectomy or pacemaker therapySeptal thickness of ≥18 mmIn a matched historical comparison, Nagueh et al showed that septal alcohol ablation is comparable to surgical myectomy with respect to hemodynamic and functional improvement.15 Long-term follow-up data are still lacking, but reports by Gietzen et al16 and Mazur et al17 indicate maintenance of clinical and hemodynamic benefits. Functional class, exercise capacity, and quality of life also are significantly improved over follow-up. The process of remodeling continues and the gradient can decrease further 6 to 12 months after the procedure. The marked reduction in symptoms is maintained and the mortality is ≈1%/year, which is ≤50% less than would be expected for HOCM. Permanent heart block requiring the implantation of a pacemaker occurs in 5% to 10% of cases. It is important to emphasize that in follow-up studies of this procedure, in addition to sustained reduction of the gradient, relief of symptoms, and increased treadmill time, a 30% reduction in ventricular wall thickness occurred.17 This observation is significant because ventricular hypertrophy is clearly an independent risk factor for SCD and heart failure. Studies in >4000 patients indicate that the procedure is safe and as effective as surgical myectomy and highly reproducible. Concern has been raised that the scarring remaining from the alcohol ablation may be a focus for ventricular arrhythmias. No evidence exists for the creation of an arrhythmogenic substrate by alcohol ablation as assessed by serial electrophysiological studies before and after the procedure,16 and none of the published reports indicate an increase in the incidence of ventricular arrhythmias or SCD during follow-up. The marked relief of symptoms together with increased exercise tolerance and regression of ventricular hypertrophy makes septal alcohol ablation an increasingly more desirable procedure.Future TherapyGenetic screening would have significant prevention, diagnostic, and therapeutic benefits, but it is not available. Screening for >200 mutations in 11 genes is a technological challenge,18 and no laws are in place to obtain routine permission or to protect the privacy of an individual from its many implications (eg, life and medical insurance). The combination of genetic screening and tissue Doppler detection of preclinical disease makes a compelling argument for the acceleration of technical and legislative progress. Our recent therapeutic findings in genetic animal models of HCM add further impetus. In the transgenic mouse model of HCM induced by expressing a human troponin T mutation, the phenotype was essentially reversed with losartan.19 In the transgenic rabbit model of HCM induced by the expression of βMHC mutation, the phenotype was reversed by simvastatin.20 Studies are ongoing to determine whether the phenotype can be prevented in animal models, and a pilot clinical study has been initiated in patients with HCM.Dr Roberts completed this work during his tenure at the Baylor College of Medicine. He is currently affiliated with the University of Ottawa Heart Institute, Ottawa, Canada..This work was supported by a grant from the National Heart, Lung, and Blood Institute, Gene Modifier Grant (1 RO1 HL68884-01). We greatly appreciate the administrative assistance of Deborah Graustein and Moira Long in the preparation of the manuscript and graphics.FootnotesCorrespondence to Robert Roberts, MD, FACC, 40 Ruskin St, Ottawa, Ontario K1Y 4W7, Canada. References 1 Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003; 348: 295–303.CrossrefMedlineGoogle Scholar2 Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001; 344: 1823–1831.CrossrefMedlineGoogle Scholar3 Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002; 109: 357–362.CrossrefMedlineGoogle Scholar4 Marian AJ, Yu QT, Mann DL, et al. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. Circ Res. 1995; 77: 98–106.CrossrefMedlineGoogle Scholar5 Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001; 33: 655–670.CrossrefMedlineGoogle Scholar6 Kai H, Muraishi A, Sugiu Y, et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 1998; 83: 594–601.CrossrefMedlineGoogle Scholar7 Derchi G, Bellone P, Chiarella F, et al. Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy. Am J Cardiol. 1992; 70: 1502–1504.CrossrefMedlineGoogle Scholar8 Lakkis N, Nagueh S, Killip D, et al. Nonsurgical septal reduction therapy for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor Experience (1996–1999). J Interv Cardiol. 2000; 13: 157–159.CrossrefGoogle Scholar9 Brugada R, Kelsey W, Lechin M, et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med. 1997; 45: 542–551.MedlineGoogle Scholar10 Marian AJ, Zhao G, Seta Y, et al. Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. Circ Res. 1997; 81: 76–85.CrossrefMedlineGoogle Scholar11 Rust EM, Albayya FP, Metzger JM. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. J Clin Invest. 1999; 103: 1459–1467.CrossrefMedlineGoogle Scholar12 Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003; 24: 1965–1991.CrossrefMedlineGoogle Scholar13 Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995; 346: 211–214.CrossrefMedlineGoogle Scholar14 Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998; 98: 2415–2421.CrossrefMedlineGoogle Scholar15 Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001; 38: 1701–1706.CrossrefMedlineGoogle Scholar16 Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999; 20: 1342–1354.CrossrefMedlineGoogle Scholar17 Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001; 103: 1492–1496.CrossrefMedlineGoogle Scholar18 Marian AJ, Roberts R. To screen or not is not the question—it is when and how to screen. Circulation. 2003; 107: 2171–2174.LinkGoogle Scholar19 Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001; 103: 789–791.CrossrefMedlineGoogle Scholar20 Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001; 104: 317–324.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Khan A, Fassa A, Dangas D and Sigwart U (2022) Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Interventional Cardiology, 10.1002/9781119697367.ch51, (539-546), Online publication date: 3-Jun-2022. McMahon C and Ganame J (2021) Hypertrophic Cardiomyopathy Echocardiography in Pediatric and Congenital Heart Disease, 10.1002/9781119612858.ch36, (772-793), Online publication date: 27-Dec-2022. Gabrusenko S, Gudkova A, Koziolova N, Alexandrova S, Berseneva M, Gordeev M, Dzemeshkevich S, Zaklyazminskaya E, Irtyuga O, Kaplunova V, Kostareva A, Krutikov A, Malenkov D, Novikova T, Saidova M, Sanakoev M and Stukalova O (2021) 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy, Russian Journal of Cardiology, 10.15829/1560-4071-2021-4541, 26:5, (4541) Jha A and Malik V (2017) Diagnosis and Management of Ischemic Mitral Regurgitation: Evidence-Based Clinical Decision Making at the Point of Care, Seminars in Cardiothoracic and Vascular Anesthesia, 10.1177/1089253217745363, 23:3, (268-281), Online publication date: 1-Sep-2019. Bos J and Ackerman M (2018) Hypertrophic Cardiomyopathy in the Era of Genomic Medicine Genomic and Precision Medicine, 10.1016/B978-0-12-801812-5.00005-6, (103-126), . Fassa A, Dangas G and Sigwart U (2016) Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Interventional Cardiology, 10.1002/9781118983652.ch54, (517-524) McMahon C and Ganame J (2016) Hypertrophic Cardiomyopathy Echocardiography in Pediatric and Congenital Heart Disease, 10.1002/9781118742440.ch35, (677-693) Kang M, Min S, Kim S, Lee C and Park H (2015) Characteristic Clinical Features and Survival in Cats with Symptomatic Hypertrophic Cardiomyopathy, Journal of Biomedical Research, 10.12729/jbr.2015.16.4.152, 16:4, (152-158), Online publication date: 1-Dec-2015. Kung E, Perry J, Davis C, Migliavacca F, Pennati G, Giardini A, Hsia T and Marsden A (2014) Computational Modeling of Pathophysiologic Responses to Exercise in Fontan Patients, Annals of Biomedical Engineering, 10.1007/s10439-014-1131-4, 43:6, (1335-1347), Online publication date: 1-Jun-2015. Rathinam A, Sari N and Mokhtar R (2015) Normal and Fibrotic Cardiac Myocardium Tissue Identified and Reproduced in Anatomically Accurate 3D for Perioperative Usage 2015 6th International Conference on Intelligent Systems, Modelling and Simulation (ISMS), 10.1109/ISMS.2015.55, 978-1-4799-8258-5, (82-87) Poulin M, Shah A, Trohman R and Madias C (2015) Advanced Anderson-Fabry disease presenting with left ventricular apical aneurysm and ventricular tachycardia, World Journal of Clinical Cases, 10.12998/wjcc.v3.i6.519, 3:6, (519), . Michler R (2013) Surgical Options for the Management of Ischemic Cardiomyopathy, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-013-0261-6, 15:5, (518-532), Online publication date: 1-Oct-2013. Bos J, Ommen S and Ackerman M (2013) Hypertrophic Cardiomyopathies Genomic and Personalized Medicine, 10.1016/B978-0-12-382227-7.00050-1, (572-586), . Bos J, Ommen S and Ackerman M (2013) Arrhythmias and Arrhythmia Management in Hypertrophic Cardiomyopathy Electrical Diseases of the Heart, 10.1007/978-1-4471-4978-1_2, (7-24), . Iacovoni A, Spirito P, Simon C, Iascone M, Di Dedda G, De Filippo P, Pentiricci S, Boni L, Senni M, Gavazzi A and Ferrazzi P (2012) A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy, European Heart Journal, 10.1093/eurheartj/ehs064, 33:16, (2080-2087), Online publication date: 2-Aug-2012. Theodos G and Kapadia S (2012) Hypertrophic Cardiomyopathy Textbook of Interventional Cardiology, 10.1016/B978-1-4377-2358-8.00052-8, (694-706), . Fifer M and Sigwart U (2011) Hypertrophic obstructive cardiomyopathy: alcohol septal ablation, European Heart Journal, 10.1093/eurheartj/ehr013, 32:9, (1059-1064), Online publication date: 1-May-2011. Fassa A and Sigwart U (2011) Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Interventional Cardiology, 10.1002/9781444319446.ch26, (394-405) Pierard L and Carabello B (2010) Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment, European Heart Journal, 10.1093/eurheartj/ehq411, 31:24, (2996-3005), Online publication date: 2-Dec-2010. Herzog E and Bucala R (2010) Fibrocytes in health and disease, Experimental Hematology, 10.1016/j.exphem.2010.03.004, 38:7, (548-556), Online publication date: 1-Jul-2010. Abbott J (2010) Feline Hypertrophic Cardiomyopathy: An Update, Veterinary Clinics of North America: Small Animal Practice, 10.1016/j.cvsm.2010.04.004, 40:4, (685-700), Online publication date: 1-Jul-2010. Okayama S, Fujimoto S, Tsutsumi T, Onoue K, Horii M, Uemura S, Sakaguchi Y and Saito Y (2010) A pediatric case of hypertrophic cardiomyopathy with mid-ventricular obstruction incidentally detected by electrocardiography, Journal of Cardiology Cases, 10.1016/j.jccase.2009.08.006, 1:2, (e67-e70), Online publication date: 1-Apr-2010. AKBARZADEH F, KAZEMI B and POURAFKARI L (2010) Supraventricular Arrhythmia Induction by an Implantable Cardioverter Defibrillator in a Patient with Hypertrophic Cardiomyopathy, Pacing and Clinical Electrophysiology, 10.1111/j.1540-8159.2009.02530.x, 33:3, (372-376), Online publication date: 1-Mar-2010. Martijn Bos J, Ommen S and Ackerman M (2010) Genetics and Genomics of Hypertrophic Cardiomyopathy Essentials of Genomic and Personalized Medicine, 10.1016/B978-0-12-374934-5.00028-3, (336-349), . Ker J (2009) The subaortic tendon as a mimic of hypertrophic cardiomyopathy, Cardiovascular Ultrasound, 10.1186/1476-7120-7-31, 7:1, Online publication date: 1-Dec-2009. van Dockum W, Knaapen P, Hofman M, Kuijer J, ten Cate F, ten Berg J, Beek A, Twisk J and van Rossum A (2009) Impact of alcohol septal ablation on left anterior descending coronary artery blood flow in hypertrophic obstructive cardiomyopathy, The International Journal of Cardiovascular Imaging, 10.1007/s10554-009-9437-2, 25:5, (511-518), Online publication date: 1-Jun-2009. Tsuji M, Kinoshita M, Imai Y, Kawamoto M and Kohara N (2009) Facioscapulohumeral muscular dystrophy presenting with hypertrophic cardiomyopathy: A case study, Neuromuscular Disorders, 10.1016/j.nmd.2008.11.011, 19:2, (140-142), Online publication date: 1-Feb-2009. Penicka M, Gregor P, Kerekes R, Marek D, Curila K and Krupicka J (2009) The Effects of Candesartan on Left Ventricular Hypertrophy and Function in Nonobstructive Hypertrophic Cardiomyopathy, The Journal of Molecular Diagnostics, 10.2353/jmoldx.2009.080082, 11:1, (35-41), Online publication date: 1-Jan-2009. Lam K and King M (2009) Echocardiography Cardiac Imaging, 10.1016/B978-0-323-05527-7.50009-3, (30-67), . Bos J, Ommen S and Ackerman M (2009) Vaccines Genomic and Personalized Medicine, 10.1016/B978-0-12-369420-1.00061-5, (716-728), . Whitten S (2008) Systolic Heart Failure in a Patient With Hypertrophic Obstructive Cardiomyopathy, Critical Care Nurse, 10.4037/ccn2008.28.5.44, 28:5, (44-52), Online publication date: 1-Oct-2008. Thai W, Antonis P, Hope S and Meredith I (2008) Quantitative and Qualitative Changes in the Resting Electrocardiograph After Percutaneous Transluminal Septal Myocardial Ablation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy, Heart, Lung and Circulation, 10.1016/j.hlc.2008.03.084, 17:5, (364-369), Online publication date: 1-Oct-2008. Sun M, Li Y, Li N, Liu H, Yin Y and Li D (2008) Preliminary clinical investigation of 99mTc-methoxyisobutylisonitrile washout rate in hypertrophic cardiomyopathy, Nuclear Medicine Communications, 10.1097/MNM.0b013e3283009f36, 29:8, (686-689), Online publication date: 1-Aug-2008. Palmer B, Wang Y, Teekakirikul P, Hinson J, Fatkin D, Strouse S, VanBuren P, Seidman C, Seidman J and Maughan D (2008) Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00644.2007, 294:4, (H1939-H1947), Online publication date: 1-Apr-2008. Maron B, Ommen S, Nishimura R and Dearani J (2008) Myths About Surgical Myectomy: Rumors of Its Death Have Been Greatly Exaggerated, The American Journal of Cardiology, 10.1016/j.amjcard.2007.10.055, 101:6, (887-889), Online publication date: 1-Mar-2008. Menon S, Bos J, Ommen S and Ackerman M Arrhythmogenic Malignancies in Hypertrophic Cardiomyopathy Electrical Diseases of the Heart, 10.1007/978-1-84628-854-8_43, (610-626) Vural A, Tiryakioğlu O, Türk T, Ata Y, Ari H, Yalçinkaya S, Erkut B, Bozat T and Özyazicioğlu A (2007) Treatment Modalities in Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy versus Percutaneous Septal Ablation, The Heart Surgery Forum, 10.1532/HSF98.20071136, 10:6, (E493-E497), Online publication date: 1-Dec-2007. Beeri R, Yosefy C, Guerrero J, Abedat S, Handschumacher M, Stroud R, Sullivan S, Chaput M, Gilon D, Vlahakes G, Spinale F, Hajjar R and Levine R (2007) Early Repair of Moderate Ischemic Mitral Regurgitation Reverses Left Ventricular Remodeling, Circulation, 116:11_supplement, (I-288-I-293), Online publication date: 11-Sep-2007. Čurila K, Pěnička M, Línková H, Knot J and Gregor P (2007) Molecular genetics in hypertrophic cardiomyopathy, Cor et Vasa, 10.33678/cor.2007.052, 49:4, (138-142), Online publication date: 1-Apr-2007. Ashrafian H and Watkins H (2007) Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications, Journal of the American College of Cardiology, 10.1016/j.jacc.2006.10.073, 49:12, (1251-1264), Online publication date: 1-Mar-2007. Honda T, Sugiyama S, Sakamoto T, Kaikita K and Ogawa H (2007) Impact of Delta-Sarcoglycan Gene Polymorphism on the Occurrence of Coronary Spastic Angina in Japanese Patients With Hypertrophic Cardiomyopathy, Circulation Journal, 10.1253/circj.71.1263, 71:8, (1263-1267), . Cahalan M (2007) Transesophageal Echocardiography for the Occasional Cardiac Anesthesiologist, ASA Refresher Courses in Anesthesiology, 10.1097/00126869-200735010-00003, 35:1, (31-40), . Gulel O, Ozturk O, Elmali M and Yazici M (2007) Rare clinical presentation of nonobstructive hypertrophic cardiomyopathy: Apical aneurysm with thrombus, International Journal of Cardiology, 10.1016/j.ijcard.2006.07.221, 114:1, (E31-E33), Online publication date: 1-Jan-2007. Buchhorn R, Eicken A, Gildein H, Kreuder J, Paul T, Schmaltz A and Schulze-Neick I (2007) Erkrankungen des Herzens Therapie in der Kinder- und Jugendmedizin, 10.1016/B978-343723200-8.50030-5, (917-965), . Lind J, Chiu C and Semsarian C (2014) Genetic basis of hypertrophic cardiomyopathy, Expert Review of Cardiovascular Therapy, 10.1586/14779072.4.6.927, 4:6, (927-934), Online publication date: 1-Nov-2006. Zhu Y, Rajan S, Kurian V and Liu Z (2006) Surgical outcomes and strategy of hypertrophic obstructive cardiomyopathy, Journal of Zhejiang University SCIENCE B, 10.1631/jzus.2006.B0148, 7:2, (148-153), Online publication date: 1-Feb-2006. July 12, 2005Vol 112, Issue 2 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000146788.30724.0APMID: 16009810 Originally publishedJuly 12, 2005 Keywordsablation, alcoholgeneticsdeath, suddencardiomyopathyhypertrophyPDF download Advertisement SubjectsCardiomyopathy
Referência(s)